Forest plot comparing EDT versus standard-duration thromboprophylaxis in hospitalized medically ill patients for the primary efficacy endpoint (symptomatic VTE or VTE-related death) and the primary safety endpoint (major or fatal bleeding).

Black solid square markers and associated solid lines represent summary RR and 95% CI of each trial listed in the left column. The size of black markers is proportional to standard error of effect estimate. The numerical estimates in the right columns are RRs with 95% CI of each trial listed in the left column. The hollow blue diamond is summary RR and 95% CI for VTE or VTE-related death, whereas the hollow red diamond is summary RR for major or fatal bleeding. ADOPT, Apixaban Dosing to Optimize Protection from Thrombosis; APEX, Acute Medically Ill Venous Prevention with Extended Duration Betrixaban; BID, two times a day; CI, confidence interval; EDT, extended-duration thromboprophylaxis; EXCLAIM, Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization; MAGELLAN, Multicenter, Randomized, Parallel Group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Acutely Ill Medical Patients Comparing Rivaroxaban with Enoxaparin; MARINER, Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk; OD, once daily; RR, risk ratio; VTE, venous thromboembolism.